A late-November 2025 weekend saw former President Donald Trump tout dramatic declines in prescription drug prices, claiming reductions of 700% thanks to most-favored-nation pricing deals and other administration actions. The assertions were quickly tested in the court of public opinion on social media, where Stocktwits’ official X account weighed in with a blunt counterpoint.
Stocktwits posted a response that captured the moment: “Math is hard, $DJT,” reminding followers that a 700% reduction is mathematically implausible. The remark underscored the broader skepticism surrounding the price claims, even as Trump and his White House allies cited ongoing pricing talks with major drugmakers.
The Independent’s John Bowden frames the piece around the clash between political messaging on drug costs and the realities of pharmaceutical pricing. Reporters note that while Pfizer and other firms have entered into deals intended to lower costs, the arithmetic of subtracting hundreds of percent from list prices does not hold up under scrutiny. Critics point to the nuance in price changes, subsidies, and tariff considerations that shape costs rather than a simple one-quote drop.
In context, Trump’s team has pointed to measures such as MFN-style pricing discussions and a framework branded as TrumpRx to argue that drug costs are falling. However, policy experts and fact-checkers have warned that such figures are hyperbolic and not supported by standard price metrics, with analyses often showing mixed or sector-wide shifts rather than uniform cuts across the board. The chatter around the claims sits amid broader debates over Obamacare subsidies and health‑care policy, and ongoing negotiations with industry players.
The story, rooted in Washington, D.C. reporting, highlights the friction between bold political claims about lowering drug prices and the more measured accounting used by economists, lawmakers, and watchdogs who track how policy translates into real-world costs.
Disclosure: We may earn a commission when you make a purchase through the ads.